ImmunityBio Inc. Common Stock vs MetLife Inc. Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.33B), while MetLife Inc. Common Stock trades at $98.97 (market cap $60.87B). The key difference: MetLife Inc. Common Stock is far larger — about 5.9× ImmunityBio Inc. Common Stock's market cap, and MetLife Inc. Common Stock pays a 2.47% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and MetLife Inc. Common Stock for 0 Days on average.
| IBRX | MET | |
|---|---|---|
Market Cap | $10.33B | $60.87B |
Volume | 11,745,198 | 3,175,937 |
Sector | Health | Financials |
52-Week High | $11.55 | $99.95 |
52-Week Low | $1.98 | $67.70 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.79B | $81.79B |
Dividend Yield | — | 2.47% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →